Cyclooxygenase products are metabolized by o-oxidation as well as p-oxidation. Children with Zellweger syndrome (ZS) are characterized by peroxisome deficiency. To evaluate the role of peroxisomal p-oxidation on cyclooxygenase metabolites, the degradation of endogenous prostanglandin (PC) E,, prostacyclin, and thromboxane (Tx) A, was assessed in children with ZS (n = 7) and in healthy children (n = 7). PGE,, prostacyclin, TxB,, and their major urinary metabolites 7a-hydroxy-5,ll-dioxotetranor-prosta-1,16-dioic acid, 2,3-dinor-6-0x0-PGF,,, and 2,3-dinor-TxB,, respectively, were measured in urine by gas chromatography-mass spectrometry/mass spectrometry. The median excretion of healthy children was 17.9 ng of 7a-hydroxy-5,ll-dioxo-tetranor-prosta-l,l6-dioic acidlmg creatinine (interquartile range, 6.3 to 19.4 nglmg), 0.38 ng of 2,3-dinor-6-0xo-PGF,~/rng creatinine (interquartile range, 0.34 to 0.70 nglmg), and 0.36 ng of 2,3-dinor-TxB2/mg creatinine (interquartile range, 0.14 to 0.54 nglmg). In contrast, none of these metabolites could be detected in urine of children with ZS ( p < 0.002). However, we identified in the urine of these children a new metabolite of PGE, as 11-hydroxy-9,15-dioxo-prost-5-en-1,20-dioic acid by gas chromatography-mass spectrometry, and we confirmed the presence of 9,ll-dihydroxy-150x0-prost-5-en-1,20-dioic acid the main urinary metabolite of PGF, in ZS. Importantly, these two metabolites were only detectable in urine of children with ZS. Furthermore, we found highly elevated amounts of PGE,, 6-0x0-PGF,,, and TxB, in urine from children with ZS compared with the amounts eliminated by healthy children (all parameters, p < 0.002). The present findings demonstrate an impaired degradation of PG and Tx in ZS on the level of P-oxidation. These data strongly support the hypothesis that prostanoids are exclusively P-oxidized by the peroxisomal pathway in vivo. (Pediatr Res 36: 449-455, 1994) Abbreviations PC, prostaglandin Tx, thromboxane LT, leukotriene PGE-MUM, prostaglandin E major urinary metabolite (7a-hydroxy-5,11-dioxo-tetranor-prosta-l,l6-dioic acid) PGF-MUM, prostaglandin F major urinary metabolite (5a,7a-dihydroxy-ll-oxo-tetranor-prosta-1,16-dioic acid) RP-HPLC, reversed-phase high-performance liquid chromatography GC-MS, gas chromatography-mass spectrometry CC-MSIMS, gas chromatography-mass spectrometry/mass spectrometry PFB, pentafluorobenzyl CAD, collisionally activated dissociation NICI, negative-ion chemical ionization 
Although the initial metabolic reaction leading to 15-0x0-13,14-dihydro-prostanoids is well elucidated, little is known about the site of B-oxidation of prostanoids. Experiments with isolated rat liver mitochondria have suggested that these organelles are able to p-oxidize prostanoids, and therefore it was generally accepted that mitochondrial p-oxidation is the major pathway (5) . Recently, however, it was demonstrated that rat liver peroxisomes p-oxidize PG at a rate similar to or even higher than that of mitochondria (6) .
Mitochondria catabolize fatty acids completely, whereas peroxisomes predominantly perform only two consecutive $-oxidations (7) . This finding further supports a role of peroxisomes in vivo, because dinor as well as tetranor metabolites of eicosanoids can be detected in urine. Taken together, these results suggest that prostanoids can be p-oxidized by the peroxisomal pathway as well as by the mitochondrial pathway. It was therefore a challenge to evaluate the relative contribution of these two organelles to p-oxidation of prostanoids in vivo. Children with ZS, a rare hereditary disorder that is characterized by the complete absence of peroxisomes and in most cases by intact mitochondria (8, 9) , are uniquely suited to investigate the contribution of peroxisomal $-oxidation of prostanoids.
Recently, we reported that LT, which are arachidonic acid metabolites as well, are p-oxidized in peroxisomes and that $-oxidation proceeds from the wend (10) . To verify our in vitro findings, we analyzed urine from children with ZS for LT metabolites (11) . In contrast to healthy children, o-carboxy-tetranor-Lm was not detectable in urine of children with ZS. Instead of LTE,, N-acetyl-LTE, and o-carboxy-LTE, accumulated in urine of these children. Furthermore, unexpectedly high amounts of LTB, were found in urine of patients with ZS (11) . This was surprising because in monkeys LTB, was extensively catabolized by osxidation followed by p-oxidation (12) . Our data, obtained from children with ZS, clearly demonstrate that LT are mainly degraded by peroxisomal poxidation in vivo in humans (11) . However, it is difficult to compare the metabolism of LT with that of PG because LT are, for unknown reasons, exclusively metabolized starting from C20, whereas p-oxidation of PG commences at C1.
To investigate the fate by which PG are p-oxidized in humans, it is useful to measure the urinary index metabolites of endogenous PG synthesis. Studies with radiolabeled PGE,, PGI,, and TxB, have shown that PGE-MUM, 2,3-dinor-6-oxo-PGF,,, and 2,3-dinor-TxB2 are the major urinary metabolites of these primary cyclooxygenase products in humans (13) (14) (15) . We have developed stable isotope dilution assays to identify and quantify these metabolites unequivocally by GC-MSIMS. In the present study, we measured the excretion of these metabolites and their precursors in children with ZS and in healthy children.
METHODS
Patients. Seven children with ZS and seven age-and sex-matched healthy infants were included in this study. All children exhibited the characteristic clinical and biochemical abnormalities described for ZS (8) . The biochemical characteristics of the children with ZS (children designated as 2 to 8) have recently been published (11) . Mitochondria1 p-oxidation activity was found to be in the range of normal subjects (11) . Convulsions were reported from all patients. None of the children with ZS had signs of cholestasis, liver failure, or impaired renal function. Urine was obtained from spontaneous micturition and stored at -80°C until analysis.
Materials the rat was treated with 3 mg of diclofenac {sodium[2-(2,6-dichlorophenylamino)phenylacetateJ) intraperitoneally and with 5 mg of diclofenac s.c. to inhibit endogenous cyclooxygenase synthesis (diclofenac was a kind gift from Ciba-Geigy, Basel, Switzerland).
[ 3~]~~~ was isolated from urine using solid-phase extraction followed by RP-HPLC as described below. (250 x 4.6-mm inner diameter) of C18 with 5-pm particle size (Shandon, Runcom, UK). The mobile phase consisted of acetonitrilelwater, 70130 vollvol, and was pumped at a flow rate of 2.0 mLlmin. The retention volumes of the PFB-MO derivatives of unlabeled and labeled PG were 6 mL for 2,3-dinor-6-0x0-PGF,, and 2,3-dinor-TxB,, 8 mL for 6-0x0-PGF,, and TxB,, 12 mL for PGE,, and-16 mL for PGE-MUM:-TWO-m~ fractions were collected, the radioactivity was determined, and then the fractions were vortex-mixed with 6 mL of ethylacetate for 2 min. The final recovery for all PG was in the range of 4040%. The coefficients of variation for the retention volume were lower than 5% for all PG. The phases were separated, and the organic layer was decanted and dried over sodium sulfate. The solvents were evaporated to dryness under nitrogen, and the residue was treated with 20 p L of N,O-bis(TMS)trifluoroacetamide and allowed to react at 60°C for 1 h.
GC-MSIMS. GC-MS/MS has been shown to be the method of choice for the analysis of eicosanoids in biologic samples (17) . In the present study, we used GC-MS/MS to quantitate prostanoids in urine. GC-MS/MS was performed on a Finnigan MAT TSQ 45 triple-stage quadrupole mass spectrometer equipped with a Finnigan gas chromatograph, model 9611 (San Jose, CA). A fused silica capillary column OV-1 (25-m x 0.25-mm inner diameter, 0.25-pm film thickness) from Macherey-Nagel (Diiren, Germany) was used. Helium was used as a carrier gas at a pressure of 55 kPa. Injector, interface, and ion source were kept at 280"C, 290°C, and 140"C, respectively. For NICI, methane was used as a reagent gas at a pressure of 65 Pa. Argon was used for CAD at a pressure of 0.2 Pa. The collision energy was set to 14 eV for all PG. The electron energy was 90 eV and the emission current 200 pA. The electron multiplier voltage was 2500 V. The following pairs of mass to charge ratios ( d z ) for the parent ions ([M-PFBI-) and the corresponding daughter ions of labeled and unlabeled compounds were used: 5901586 and 2441240 for both 2,3-dinor-6-0x0-PGF,, and 2,3-dinor-TxB,; 6181614 and 2721268 for both 6-0x0-PGF,, and TxB,; 5281524 and 2721268 for PGE,; and 6411637 and 3531349 for PGE-MUM. One to 2.5 p L were injected into the GC-MSIMS system in the splitless mode using oven temperature programs. The inter-and intraassay coefficients of variation for all prostanoids were within the range of 1.5 to 3.5% and 0.8 to 1.9%, respectively. The detection limit of the method was about 10 n g L for PGE-MUM and 5 ng/L for the other prostanoids.
Statistics. Statistical analysis was performed by using the Wilcoxon signed-rank test.
RESULTS
Excretion of the major urinary cyclooxygenase end metabolites in urine. The urinary excretion of PGE-MUM, 2,3-dinor-6-0x0-PGF,,, and 2,3-dinor-TxB, of children with ZS as well as of matched healthy children is shown in Figure 1 . In children with ZS, none of these metabolites could be detected in urine despite detection limits of 10, 5, and 5 ng/L urine for PGE-MUM, 2,3-dinor-6-0x0-PGF,,, and 2,3-dinor-TxB,, respectively (Fig. 2) . Healthy children excreted median 17. dinor-6-0x0-PGF,Jmg of creatinine, and median 0.37 (interquartile range, 0.14 to 0.54) ng of 2,3-dinor-TxB,/mg of creatinine into urine. The amounts of PGE-MUM excreted by healthy children were at least 180-fold, those of 2,3-dinor-6-0x0-PGF,, 13-fold, and those of 2,3-dinorTxB, 10-fold higher than those excreted by children with
ZS.
Exrmtbn of prinuup cycboxygenase metabolites in urine. The excretion of P G b , 6-0x0-PGF,,, and TxB, in urine of healthy children and children with ZS is shown in Figure 3 . The children with ZS excreted significantly ( p < 0.002) larger amounts of PGE,, 6-0x0-PGF,,, and ' TkB, into urine compared with the healthy children. The amounts of PGE, were 60-fold, those of 6-0x0-PGF,, -HC ZS HC ZS HC ZS Figure 3 . Urinary excretion of P G b , 6-0x0-PGF,,, and TxB, by healthy children (HC) and children with ZS (ZS). The primary PG were measured by GC-MS/MS. Children with ZS excreted significantly ( p c 0.002) higher amounts of PGE,, 6-oxo-PGF,,, and TxB, into urine than matched healthy children.
30-fold, and those of TxB, 80-fold higher than those excreted by healthy children.
Evaludion of the mqior urinary me&Mite of the E PG in ZS. A 1-mL aliquot of a urine sample from children with ZS was subjected to solid-phase extraction and the residue derivatized by PFB esterification, methoximation, and silylation as described in Methods. One-FL aliquots were injected into the GC-MSiMS system and analyzed in the NICI mode by GC-MS as well as GC-MSiMS. Figure 4 shows NICI mass spectra of the diPFB-diMO-TMS derivative of PGE-MUM (lower panel) and of the corresponding derivative of a compound with a relative retention time of 601 and m/z 511. These were also increased by 54 D with respect to PGE-MUM and probably resulted from consecutive fragmentation of one TMSOH group and two MO groups. This compound has two 0x0 groups because methoximation using 2~,-methoxyamine hydrochloride instead of the unlabeled reagent resulted in the most intense signal at m/z 697 in the mass spectrum (data not shown), which was increased by 6 D with respect to the unlabeled methoximated derivative (Fig. 4) . Furthermore, the appearance of a less intense signal at m/z 511 but not at m/z 517 in the , were subjected to CAD under identical conditions. CAD of the parent ion at m/z 697.7 resulted in a mass spectrum very similar to that of m/z 637.7 of the PGE-MUM derivative (Fig. 5) . All intense signals appearing in the mass spectrum of the PGE-MUM are also present in the mass spectrum of the unknown metabolite, but they all are increased by 60 D. The presence of the daughter ion at m/z 499 ([M-PFB-PFBOHI-) in the mass spectrum of the unknown metabolite is strong evidence that this metabolite is a dicarboxylic compound. Thus, this compound is a dicarboxylic-dioxo-monoxydroxy eicosanoid. This metabolite could be exclusively identified in urine from all children with ZS by GC-MS and GC-MSMS. Because no synthetic standard of this compound is available, exact quantitation of this new metabolite of PGE, was not possible. However, the spectrometric and chromatographic data combined with the lack of PGE-MUM in the urine of patients with ZS and the presence of PGE-MUM in the urine of healthy children strongly suggest that this metabolite is identical with lla-hydroxy-9,15-dioxo-prost-5-en-1,2O-dioic acid. Major urinary metabolite ofPGF,, in children with ZS. In the present study, we also identified by GC-MS and GC-MSMS (Fig. 6 ) the new urinary metabolite of PGF,, which was recently discovered in urine of children with ZS (18) . In the NICI mass spectrum of this metabolite, the most intense signal was observed at m/z 736 ([M-PFBI-). CAD of this ion resulted in the formation of intense daughter ions at m/z 538 ([M-PFB-PFBOHI-), which is characteristic for PFB esters of dicarboxylic acids; at m/z 448 ([M-PFB-PFBOH-TMSOHI-); and at m/z 358 ([M-PFB-PFBOH-2xTMSOHI-). All these signals are increased by 54 D [CH=CH-(CH,),] with respect to the signals of the PFB-MO-TMS derivative of PGF-MUM. On the basis of the present data, we suggest that this metabolite is identical with 9,ll-dihydroxy-15-0x0-prost-5-ene-1,20-dioic acid, which is identical with that described by Diczfalusy et al. (18) .
DISCUSSION
To investigate whether PG and Tx are P-oxidized by the peroxisomal pathway in vivo, the major urinary metabolites of the E PG (PGE-MUM), PGI, (2,3-dinor-6-0x0-PGF,cu), and TxA, (2,3-dinor-TxB,) were assessed in urine of children with ZS and healthy children. In contrast to healthy children, none of these p-oxidized major urinary metabolites could be detected by GC-MSMS in urine of children with ZS. The complete absence of PGF-MUM and 2,3-dinor-TxB, in the urine from children with ZS is in line with other reports (18, 19) . Importantly, we found a new metabolite of the E PG in urine. This new metabolite was identified by GC-MS and GC-MSMS as ll-hydroxy-9,15-dioxo-prost-5-en-1,20-dioic acid. A hy- pothetical pathway for the formation of this new metabolite is shown in Figure 7 . Characteristically, this new metabolite is w-but not P-oxidized. This demonstrates that also the E prostanoids are exclusively p-oxidized in peroxisomes. In addition, using the same methodology, we identified a second metabolite as 9,ll-dihydroxy-15-0x0-prost-5-en-1,20-dioic acid in urine from children with ZS. This metabolite is probably identical with a new major metabolite of PGF, in urine of children with ZS described by Diczfalusy et al. (18) . Because no suitable internal standard is available, quantification of these novel metabolites by GC-MSMS was not possible.
The fact that these two novel metabolites are only detectable in urine of children with ZS, together with the complete absence of PGE-MUM, 2,3-dinor-6-0x0-PGF,,, and 2,3-dinor-TxB,, demonstrates two interesting facts. First, it reflects an impaired P-oxidation of PG in these children, because the two novel metabolites are the immediate precursors of the p-oxidized PGE-MUM and PGF-MUM. Second, it shows that @-oxidation is not an essential requirement for w-oxidation of PG. In addition, TxB, is exclusively P-oxidized in peroxisomes because 2,3-dinor-TxB2 was not detectable in urine of children with ZS. The absence of detectable amounts of urinary PGE-MUM, 2,3-dinor-6-0x0-PGF,,, and 2,3-dinor-TxB, is apparently useful for diagnosis of impaired peroxisoma1 @-oxidation.
The markedly increased amounts of PGE,, 6-0x0-PGF,,, and TxB, in urine of children with ZS compared with the amounts excreted by healthy children is of considerable interest, because these metabolites have been shown to reflect renal PG and Tx synthesis. However, this assumption is valid only in healthy humans (20) . In children with ZS, the metabolism of circulating as well as locally produced cyclooxygenase products is impaired, and therefore systemic cyclooxygenase products could be eliminated by the kidney at a much higher rate than in healthy individuals. Although this explanation is probably valid for 64x0-PGF,, and TxB,, it is does not explain the enhanced excretion of PGE, into urine because PGE, is extremely rapidly metabolized (13) in the lung by 15-hydroxy-dehydrogenase and 13A-reductase to 1 5 -0 x o -'~~-d i h y d r o -~~~, (4) . Therefore, enhanced urinary amounts of PGE, are most likely of renal origin (21) .
On the basis of the present data, it is not possible to estimate whole-body cyclooxygenase production in children with ZS. To obtain a rough estimate of the E prostanoid production in these patients, we estimated by GC-MS/MS the amounts of 9,ll-dihydroxy-15-0x0-prost-5-en-1,20-dioic acid using [1,16-'802]PGE-MUM as an internal standard. This analysis showed that the urinary amounts of this new metabolite are at least as high as the amounts of PGE-MUM in urine from healthy children. This suggests that the synthesis of cyclooxygenase metabolites in children with ZS is comparable to that in healthy children. The consequences of these high amounts of abnormal cyclooxygenase metabolites in children with ZS is not clear. Most PG have been shown to be anticonvulsive (22) ; however, PGF, has been shown to induce grand mal-like seizures in humans (23, 24) . In conclusion, the present paper shows that cyclooxygenase products are exclusively p-oxidized by the peroxisomal pathway in vivo in humans. We detected a novel metabolite of the E PG in urine of children with ZS. This metabolite is o-but not P-oxidized.
